GW Pharmaceuticals PLC (NASDAQ:GWPH) received a $208.00 price target from equities researchers at Cantor Fitzgerald in a research note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 80.71% from the stock’s current price.

Several other analysts have also commented on the stock. Maxim Group set a $135.00 price target on shares of GW Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Monday. Zacks Investment Research raised shares of GW Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $119.00 price target for the company in a research report on Monday, July 17th. TheStreet lowered shares of GW Pharmaceuticals PLC from a “c-” rating to a “d+” rating in a research report on Wednesday, May 10th. BidaskClub raised shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Finally, ValuEngine raised shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Five investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. GW Pharmaceuticals PLC has an average rating of “Buy” and an average target price of $148.16.

Shares of GW Pharmaceuticals PLC (NASDAQ GWPH) traded down 5.16% on Tuesday, hitting $109.16. 256,306 shares of the company traded hands. The firm’s 50-day moving average is $105.72 and its 200 day moving average is $113.95. GW Pharmaceuticals PLC has a 1-year low of $79.62 and a 1-year high of $137.88. The firm’s market capitalization is $2.76 billion.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.50) by $0.20. GW Pharmaceuticals PLC had a negative return on equity of 22.81% and a negative net margin of 1,021.38%. The business had revenue of $2.04 million during the quarter, compared to analysts’ expectations of $2.07 million. During the same period last year, the company earned ($0.06) earnings per share. The firm’s revenue was down 23.0% compared to the same quarter last year. On average, analysts anticipate that GW Pharmaceuticals PLC will post ($5.10) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/08/cantor-fitzgerald-reiterates-208-00-price-target-for-gw-pharmaceuticals-plc-gwph.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Alliancebernstein L.P. raised its position in shares of GW Pharmaceuticals PLC by 4.6% in the first quarter. Alliancebernstein L.P. now owns 286,475 shares of the biopharmaceutical company’s stock worth $34,646,000 after buying an additional 12,519 shares during the period. Blair William & Co. IL acquired a new position in shares of GW Pharmaceuticals PLC during the first quarter worth about $207,000. Victory Capital Management Inc. raised its position in shares of GW Pharmaceuticals PLC by 10.4% in the first quarter. Victory Capital Management Inc. now owns 283,025 shares of the biopharmaceutical company’s stock worth $34,229,000 after buying an additional 26,638 shares during the period. Pictet Asset Management Ltd. raised its position in shares of GW Pharmaceuticals PLC by 81.1% in the first quarter. Pictet Asset Management Ltd. now owns 128,571 shares of the biopharmaceutical company’s stock worth $15,549,000 after buying an additional 57,578 shares during the period. Finally, Creative Planning raised its position in shares of GW Pharmaceuticals PLC by 179.3% in the first quarter. Creative Planning now owns 2,497 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 1,603 shares during the period. Hedge funds and other institutional investors own 75.77% of the company’s stock.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.